Cognition Therapeutics, Inc.
General ticker "CGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $116.4M (TTM average)
Cognition Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -8.3%.
Estimated limits based on current volatility of 5.5%: low 0.72$, high 0.80$
Factors to consider:
- Total employees count: 14 (-44.0%) as of 2025
- Top business risk factors: No approved products, Significant losses, Need additional capital, Clinical trial failure, Regulatory and compliance
- Current price 17.8% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.89$, 2.52$]
- 2026-12-31 to 2027-12-31 estimated range: [0.74$, 2.09$]
Financial Metrics affecting the CGTX estimates:
- Positive: with PPE of -4.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: 0 < Interest expense per share per price, % of 0.01
- Negative: negative Industry operating cash flow (median)
- Negative: 69.38 < Shareholder equity ratio, % of 70.82 <= 81.92
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CGTX quotes
Long-term CGTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $50.72MM | $53.97MM | $47.80MM |
| Operating Income | $-50.72MM | $-53.97MM | $-47.80MM |
| Non-Operating Income | $24.78MM | $20.00MM | $24.31MM |
| Interest Expense | $0.03MM | $0.03MM | $0.01MM |
| R&D Expense | $37.20MM | $41.68MM | $37.19MM |
| Income(Loss) | $-25.95MM | $-33.97MM | $-23.49MM |
| Net Income(Loss)* | $-25.79MM | $-33.97MM | $-23.49MM |
| Stockholders Equity | $24.47MM | $18.75MM | $34.27MM |
| Assets | $35.16MM | $30.23MM | $48.39MM |
| Operating Cash Flow | $-16.02MM | $-28.47MM | $-24.59MM |
| Capital expenditure | $0.15MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.15MM | $-0.00MM | $0.01MM |
| Financing Cash Flow | $4.52MM | $23.57MM | $36.57MM |
| Earnings Per Share** | $-0.86 | $-0.86 | $-0.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.